Related references
Note: Only part of the references are listed.New Steps for Tobacco Control In and Outside of China
Matthew Kohrman
ASIA-PACIFIC JOURNAL OF PUBLIC HEALTH (2010)
Meta-Analysis of 15 Genome-Wide Linkage Scans of Smoking Behavior
Shizhong Han et al.
BIOLOGICAL PSYCHIATRY (2010)
Genetic Variation in Nicotine Metabolism Predicts the Efficacy of Extended-Duration Transdermal Nicotine Therapy
C. Lerman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors
Nael Al Koudsi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior
Thorgeir E. Thorgeirsson et al.
NATURE GENETICS (2010)
Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Helena Furberg et al.
NATURE GENETICS (2010)
Common and Unique Biological Pathways Associated with Smoking Initiation/Progression, Nicotine Dependence, and Smoking Cessation
Ju Wang et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics
Neal L. Benowitz
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2009)
Association of Nicotine Metabolite Ratio and CYP2A6 Genotype With Smoking Cessation Treatment in African-American Light Smokers
M. K. Ho et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Prevalence and determinants of diabetes and impaired fasting glucose among urban community-dwelling adults in Guangzhou, China
H. Wang et al.
DIABETES & METABOLISM (2009)
Attitudes and beliefs about secondhand smoke and smoke-free policies in four countries: Findings from the International Tobacco Control Four Country Survey
Andrew Hyland et al.
NICOTINE & TOBACCO RESEARCH (2009)
Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: A validation study
Robert A. Schnoll et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2009)
Toward personalized therapy for smoking cessation: A randomized placebo-controlled trial of bupropion
F. Patterson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent
Man Ki Ho et al.
PHARMACOGENETICS AND GENOMICS (2008)
Identification of novel CYP2A6*1B variants: The CYP2A6*1B allele is associated with faster in vivo nicotine metabolism
J. C. Mwenifumbo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Genetic variability in CYP2A6 and the pharmacokinetics of nicotine
Jill C. Mwenifiumbo et al.
PHARMACOGENOMICS (2007)
The role of CYP2A6 in the emergence of nicotine dependence in adolescents
Janet Audrain-McGovern et al.
PEDIATRICS (2007)
CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A
T. Fukami et al.
PHARMACOGENOMICS JOURNAL (2006)
CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking
Viba Malaiyandi et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
CYP2A6 polymorphisms in Malays, Chinese and Indians
M. Nurfadhlina et al.
XENOBIOTICA (2006)
Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation
Caryn Lerman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy
V Malaiyandi et al.
MOLECULAR PSYCHIATRY (2006)
Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms
N Minematsu et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations
Miki Nakajima et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais
Sompop Peamkrasatam et al.
DRUG METABOLISM AND PHARMACOKINETICS (2006)
CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents
SW Huang et al.
PHARMACOGENETICS AND GENOMICS (2005)
Cohort profile: The Kadoorie study of chronic disease in China (KSCDC)
ZM Chen et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2005)
Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method
JC Mwenifumbo et al.
PHARMACOGENETICS AND GENOMICS (2005)
Metabolism and disposition kinetics of nicotine
J Hukkanen et al.
PHARMACOLOGICAL REVIEWS (2005)
High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana
MA Gyamfi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians
KA Schoedel et al.
PHARMACOGENETICS (2004)
Genetically decreased CYP2A6 and the risk of tobacco dependence:: a prospective study of novice smokers
J O'Loughlin et al.
TOBACCO CONTROL (2004)
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers
M Fujieda et al.
CARCINOGENESIS (2004)
Mortality in relation to smoking: 50 years' observations on male British doctors
R Doll et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Progress in searching for susceptibility loci and genes for smoking-related behaviour
MD Li et al.
CLINICAL GENETICS (2004)
Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro
R Yoshida et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema
N Minematsu et al.
THORAX (2003)
Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes
A Madan et al.
DRUG METABOLISM AND DISPOSITION (2003)
A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins
MD Li et al.
ADDICTION (2003)
Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans
NL Benowitz et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles
C Xu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene:: Impairment of its promoter activity
M Pitarque et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Smoking cessation in China: findings from the 1996 national prevalence survey
GH Yang et al.
TOBACCO CONTROL (2001)
CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity
K Kitagawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A novel single nucleotide polymorphism altering stability and activity of CYP2A6
N Ariyoshi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population
MA Loriot et al.
PHARMACOGENETICS (2001)
Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C
N Ariyoshi et al.
PHARMACOGENETICS (2000)
Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking
EM Sellers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit
DF Gu et al.
ANNALS OF HUMAN GENETICS (2000)
Share Paper
